The terrorist attacks around the world necessitate society's continued investment in a strong defense against these unpredictable and deadly events. Infectious agents identified to pose the greatest potential threat (Category """"""""A"""""""" agents) include Variola major (smallpox), Bacillus anthracis (anthrax), Yersinia pestis (plague), Clostridium botulinum toxin (botulism), Francisella tularensis (tularaemia), and a group of RNA viruses that cause hemorrhagic fevers (VHFs). Another agent of grave concern is influenza (Flu) (Category """"""""C""""""""). Flu A and B viruses kill hundreds of thousands each year world wide and cost society tens to hundreds of billion dollars in morbidity and societal disruption. Additional concern exists over bird-to-human spread of Flu and the potential adaptation for human-to-human spread. Terrorist could take advantage of Flu's antigenic flexibility and engineer """"""""shifted"""""""" more virulent strains capable of causing worldwide pandemics. Current diagnostic assays are directed to the common human isolates of Flu A (H1N1 and H3N2) and Flu B, but no assay is available to detect all of the avian antigenic varieties of Flu A (16 HA types, 9 N types). Our laboratory has pioneered a flexible, rapid, sensitive, and specific method of simultaneously detecting multiple pathogens. Our multiplex PCR-EHA tests (Hexaplex, Pneumoplex, Adenoplex, SARS/Coronaplex, etc.) are used widely around the world. We have recently developed two BioTplex assays that detect many (15) category """"""""A"""""""" agents. However, new methods of amplified DNA detection (electronic microarrays) and nucleic acid purification now allow for the development of a single """"""""point-of-care"""""""" device that may enhance the speed, flexibility, throughput, and cost effectiveness of multiplex assays.
The Specific Aims of this application are: 1) Chemistry, we will select, optimize, and integrate sample preparation chemistry, multiplex PCRamplification systems, and electronic microarray methods to detect all antigenic variants of Flu A/B (pandemic Flu assay) and the majority of category """"""""A"""""""" bioterrorism agents (BioT assay) in an open platform mode (separate equipment for each function);2) Feasibility, to determine performance characteristics of the 3 modules in small pre-clinical studies using previously collected clinical samples;3) Automation, miniaturize, integrate, and simplify the chemistry and mechanisms of SA#1 to create 3 modules and then a fully integrated single device (prototype);4)Process development, ensure manufacturability at a reasonable cost (e.g., critical reagents, specifications, test methods, suppliers, stability, and formulation into components);5) Pre-Clinical study, test the clinical sensitivity and specificity of the newly developed assays, compared to non-molecular methods and our """"""""gold standard"""""""" not integrated molecular assays (PCR-EHA) on 1200 previously collected samples. These new assays, in an integrated single device, may allow cost effective, point-of-care diagnosis within 1-2 hrs in an outpatient setting. These goals are responsive to a recent NIAID announcement for High- Priority influenza (NOT-AI-05-013) and bio-threat (RFA AI-05-019) research.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01AI070428-05
Application #
7910505
Study Section
Special Emphasis Panel (ZAI1-GSM-M (M1))
Program Officer
Beanan, Maureen J
Project Start
2006-09-01
Project End
2012-08-31
Budget Start
2010-09-01
Budget End
2012-08-31
Support Year
5
Fiscal Year
2010
Total Cost
$1,526,585
Indirect Cost
Name
Medical College of Wisconsin
Department
Pediatrics
Type
Schools of Medicine
DUNS #
937639060
City
Milwaukee
State
WI
Country
United States
Zip Code
53226
Beck, Eric T; He, Jie; Nelson, Martha I et al. (2012) Genome sequencing and phylogenetic analysis of 39 human parainfluenza virus type 1 strains isolated from 1997-2010. PLoS One 7:e46048
Rebuffo-Scheer, Cecilia; Bose, Michael; He, Jie et al. (2011) Whole genome sequencing and evolutionary analysis of human respiratory syncytial virus A and B from Milwaukee, WI 1998-2010. PLoS One 6:e25468
Nelson, Martha I; Tan, Yi; Ghedin, Elodie et al. (2011) Phylogeography of the spring and fall waves of the H1N1/09 pandemic influenza virus in the United States. J Virol 85:828-34
Kumar, Swati; Chusid, Michael J; Willoughby, Rodney E et al. (2010) Epidemiologic Observations from Passive and Targeted Surveillance during the First Wave of the 2009 H1N1 Influenza Pandemic in Milwaukee, WI. Viruses 2:782-795
Kumar, Swati; Chusid, Michael J; Willoughby, Rodney E et al. (2009) Introduction of a Novel Swine-Origin Influenza A (H1N1) Virus into Milwaukee, Wisconsin in 2009. Viruses 1:72-83
He, Jie; Bose, Michael E; Beck, Eric T et al. (2009) Rapid multiplex reverse transcription-PCR typing of influenza A and B virus, and subtyping of influenza A virus into H1, 2, 3, 5, 7, 9, N1 (human), N1 (animal), N2, and N7, including typing of novel swine origin influenza A (H1N1) virus, during the 2009 o J Clin Microbiol 47:2772-8
Bose, Michael E; Beck, Eric T; Ledeboer, Nate et al. (2009) Rapid semiautomated subtyping of influenza virus species during the 2009 swine origin influenza A H1N1 virus epidemic in Milwaukee, Wisconsin. J Clin Microbiol 47:2779-86
Huang, Ying; Tang, Huong; Duffy, Stuart et al. (2009) Multiplex assay for simultaneously typing and subtyping influenza viruses by use of an electronic microarray. J Clin Microbiol 47:390-6
Bose, Michael E; Littrell, John C; Patzer, Andrew D et al. (2008) The Influenza Primer Design Resource: a new tool for translating influenza sequence data into effective diagnostics. Influenza Other Respi Viruses 2:23-31